0
Abstract: Poster Presentations |

OMALIZUMAB IMPROVES SYMPTOMS AND REDUCES RESCUE BETA-AGONIST USE IN OLDER PATIENTS WITH UNCONTROLLED ASTHMA FREE TO VIEW

Robert J. Maykut, MD*; Marc Massanari, PharmD; Farid Kianifard, PhD; Yamo Deniz, MD; Colin Reisner, MD; Robert Zeldin, MD; Gregory P. Geba, MD
Author and Funding Information

Novartis Pharmaceuticals Corporation, East Hanover, NJ


Chest


Chest. 2005;128(4_MeetingAbstracts):243S. doi:10.1378/chest.128.4_MeetingAbstracts.243S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  Asthma in older adults is under-diagnosed, under-treated, and the role of immunoglobulin E (IgE) in asthma is under-appreciated in this population . Therapy with omalizumab (OMA), an anti-IgE antibody, is indicated in patients with moderate to severe IgE-mediated asthma whose remain symptomatic despite inhaled corticosteroids. We conducted a pooled analysis of all double-blind placebo-controlled trials to evaluate the effect of OMA on asthma symptom score and rescue beta-agonist use in patients 50 years and older.

METHODS:  Data were combined from 5 randomized double blind placebo-controlled (PBO) trials of patients with moderate to severe IgE-mediated asthma; 4 were of 28 weeks and 1 was 32 weeks in duration. From the pooled study population comprised of 2236 patients, 601 were ≥ 50 years of age (296 OMA, 305 PBO). The change from baseline in mean total asthma symptom score [range 0 (symptom free) to 9], and in mean beta-agonist rescue puffs was assessed using an analysis of covariance. Least-squares mean treatment differences were calculated and 95% confidence intervals were constructed.

RESULTS:  The mean age of the older subgroup was 58 years; 61% were female; median IgE level was 132 IU/dl; mean percent predicted FEV1 64.6% ± 17.0%; baseline mean total asthma symptom score was 3.35 (OMA) and 3.40 (PBO), and baseline mean daily rescue beta-agonist use was 4.48 puffs (OMA) and 4.37 puffs (PBO). In this subpopulation, least-squares mean difference (OMA-PBO) for change from baseline in mean asthma symptom score was -0.26 (95% CI -0.51, -0.01; p=0.0411) and least-squares mean difference for change from baseline in rescue beta-agonist puffs was -0.47 (95% CI -0.92, -0.02; p=0.0414). The tolerability profile of OMA in the ≥ 50 year age subgroup was generally similar to that of the overall study population.

CONCLUSION:  Treatment with omalizumab significantly improved asthma symptoms and reduced beta-agonist use in older patients with moderate to severe persistent IgE-mediated asthma.

CLINICAL IMPLICATIONS:  IgE-mediated asthma is important to recognize and manage in older patients.

DISCLOSURE:  Robert Maykut, Employee I am an employee of Novartis Pharmaceuticals Corporation.

Wednesday, November 2, 2005

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543